Japan To Link Global Drug Trials To Enable 18-Month Approvals
This article was originally published in PharmAsia News
Executive Summary
Japan's Health Ministry plans to take action to speed drug approval by loosening some of its regulations, possibly including creation of a "global clinical trial institution." The agency is considering the action in recognition of the trend of an increasing number of drug makers to conduct trials in several countries at the same time. The ministry seeks to make the Japanese process comparable to those of its counterparts in the U.S. and Europe. The global institution is seen as a way for the government to meet its five-year plan launched last year to cut drug-approval time to about 18 months, compared with the four years the process requires today. (Click here for more - a subscription may be required
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
Novartis Hires Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.
Maxwellia Delivers Two UK Menstrual Health Rx-To-OTC Switches
UK switch specialist Maxwellia delivers two “me too” reclassifications in the area of women's health: Evana Heavy Period Relief and Ultravana Period Pain Relief.